Global Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook 2023

Report ID: 1239085 | Published Date: Jan 2025 | No. of Page: 114 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
    1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
    1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
        1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Comparison by Type (2021-2027)
        1.2.2 Alpha-Blocker
        1.2.3 Phosphodiesterase Type-5 Inhibitors
        1.2.4 Others
    1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
        1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application: (2021-2027)
        1.3.2 Hospitals
        1.3.3 Drugstores
        1.3.4 Others
    1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
        1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2027
        1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027
        1.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers
    2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2016-2021)
    2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2016-2021)
    2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2016-2021)
    2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites, Area Served, Product Type
    2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
        2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
        2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region
    3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
    3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
    3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
        3.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
        3.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
        3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
        3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region
        3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
        3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
        3.6.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
        3.6.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
        3.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
        3.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Type
    4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
    4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
    4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021)

5 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Application
    5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
    5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)
    5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)

6 Key Companies Profiled
    6.1 Eli Lilly
        6.1.1 Eli Lilly Corporation Information
        6.1.2 Eli Lilly Description and Business Overview
        6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.1.5 Eli Lilly Recent Developments/Updates
    6.2 GlaxoSmithKline
        6.2.1 GlaxoSmithKline Corporation Information
        6.2.2 GlaxoSmithKline Description and Business Overview
        6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.2.5 GlaxoSmithKline Recent Developments/Updates
    6.3 Astellas Pharma
        6.3.1 Astellas Pharma Corporation Information
        6.3.2 Astellas Pharma Description and Business Overview
        6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.3.5 Astellas Pharma Recent Developments/Updates
    6.4 Sanofi
        6.4.1 Sanofi Corporation Information
        6.4.2 Sanofi Description and Business Overview
        6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.4.5 Sanofi Recent Developments/Updates
    6.5 Pfizer
        6.5.1 Pfizer Corporation Information
        6.5.2 Pfizer Description and Business Overview
        6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.5.5 Pfizer Recent Developments/Updates
    6.6 Abbott
        6.6.1 Abbott Corporation Information
        6.6.2 Abbott Description and Business Overview
        6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.6.5 Abbott Recent Developments/Updates
    6.7 Allergan
        6.6.1 Allergan Corporation Information
        6.6.2 Allergan Description and Business Overview
        6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.4.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.7.5 Allergan Recent Developments/Updates
    6.8 TEVA
        6.8.1 TEVA Corporation Information
        6.8.2 TEVA Description and Business Overview
        6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.8.5 TEVA Recent Developments/Updates
    6.9 Mylan
        6.9.1 Mylan Corporation Information
        6.9.2 Mylan Description and Business Overview
        6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.9.5 Mylan Recent Developments/Updates
    6.10 Novartis
        6.10.1 Novartis Corporation Information
        6.10.2 Novartis Description and Business Overview
        6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.10.5 Novartis Recent Developments/Updates
    6.11 Merck
        6.11.1 Merck Corporation Information
        6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description and Business Overview
        6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
        6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
        6.11.5 Merck Recent Developments/Updates

7 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
    7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
    7.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
    8.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

9 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
    9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
    9.2 Benign Prostatic Hyperplasia (BPH) Drugs Growth Drivers
    9.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
    9.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

10 Global Market Forecast
    10.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2022-2027)
        10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2022-2027)
    10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2022-2027)
        10.2.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2022-2027)
    10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2022-2027)
        10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer
List of Tables
    Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate Comparison by Type (2021-2027)
    Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Comparison by Application (2021-2027)
    Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
    Table 4. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered in This Study
    Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Manufacturers (2016-2021)
    Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2016-2021)
    Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
    Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2016-2021)
    Table 9. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Manufacturers (2016-2021)
    Table 10. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites and Area Served
    Table 11. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2020)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
    Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
    Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
    Table 18. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
    Table 19. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
    Table 20. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 21. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
    Table 22. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
    Table 23. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
    Table 24. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 25. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
    Table 26. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
    Table 27. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
    Table 28. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
    Table 29. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
    Table 30. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
    Table 31. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
    Table 32. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 33. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
    Table 34. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
    Table 35. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
    Table 36. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 37. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
    Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2016-2021)
    Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
    Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Type (2016-2021)
    Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2016-2021)
    Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2016-2021)
    Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2016-2021)
    Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
    Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Application (2016-2021)
    Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2016-2021)
    Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2016-2021)
    Table 48. Eli Lilly Corporation Information
    Table 49. Eli Lilly Description and Business Overview
    Table 50. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 51. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 52. Eli Lilly Recent Developments/Updates
    Table 53. GlaxoSmithKline Corporation Information
    Table 54. GlaxoSmithKline Description and Business Overview
    Table 55. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 56. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 57. GlaxoSmithKline Recent Developments/Updates
    Table 58. Astellas Pharma Corporation Information
    Table 59. Astellas Pharma Description and Business Overview
    Table 60. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 61. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 62. Astellas Pharma Recent Developments/Updates
    Table 63. Sanofi Corporation Information
    Table 64. Sanofi Description and Business Overview
    Table 65. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 66. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 67. Sanofi Recent Developments/Updates
    Table 68. Pfizer Corporation Information
    Table 69. Pfizer Description and Business Overview
    Table 70. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 71. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 72. Pfizer Recent Developments/Updates
    Table 73. Abbott Corporation Information
    Table 74. Abbott Description and Business Overview
    Table 75. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 76. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 77. Abbott Recent Developments/Updates
    Table 78. Allergan Corporation Information
    Table 79. Allergan Description and Business Overview
    Table 80. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 81. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 82. Allergan Recent Developments/Updates
    Table 83. TEVA Corporation Information
    Table 84. TEVA Description and Business Overview
    Table 85. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 86. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 87. TEVA Recent Developments/Updates
    Table 88. Mylan Corporation Information
    Table 89. Mylan Description and Business Overview
    Table 90. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 91. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 92. Mylan Recent Developments/Updates
    Table 93. Novartis Corporation Information
    Table 94. Novartis Description and Business Overview
    Table 95. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 96. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 97. Novartis Recent Developments/Updates
    Table 98. Merck Corporation Information
    Table 99. Merck Description and Business Overview
    Table 100. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 101. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
    Table 102. Merck Recent Developments/Updates
    Table 103. Production Base and Market Concentration Rate of Raw Material
    Table 104. Key Suppliers of Raw Materials
    Table 105. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
    Table 106. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
    Table 107. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
    Table 108. Benign Prostatic Hyperplasia (BPH) Drugs Growth Drivers
    Table 109. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
    Table 110. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
    Table 111. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2027) & (M Units)
    Table 112. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2022-2027)
    Table 113. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
    Table 114. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2022-2027)
    Table 115. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2027) & (M Units)
    Table 116. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2022-2027)
    Table 117. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
    Table 118. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2022-2027)
    Table 119. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2022-2027) & (M Units)
    Table 120. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2022-2027)
    Table 121. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
    Table 122. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2022-2027)
    Table 123. Research Programs/Design for This Report
    Table 124. Key Data Information from Secondary Sources
    Table 125. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
    Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2020 & 2027
    Figure 3. Alpha-Blocker Product Picture
    Figure 4. Phosphodiesterase Type-5 Inhibitors Product Picture
    Figure 5. Others Product Picture
    Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2020 & 2027
    Figure 7. Hospitals
    Figure 8. Drugstores
    Figure 9. Others
    Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2016-2027 (US$ Million)
    Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027 (M Units)
    Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
    Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2020
    Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2020
    Figure 16. The Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players: Market Share by Revenue in 2020
    Figure 17. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
    Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
    Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
    Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
    Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2020
    Figure 22. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 23. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 24. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 25. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 26. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 27. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 28. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 29. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 30. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 31. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 32. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 33. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 34. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 35. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 36. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 37. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 38. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 39. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 42. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 43. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 44. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 45. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 46. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2016-2021)
    Figure 47. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2016-2021)
    Figure 48. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2020
    Figure 49. Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2016-2021)
    Figure 50. Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2020
    Figure 51. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
    Figure 52. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
    Figure 53. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
    Figure 54. Channels of Distribution
    Figure 55. Distributors Profiles
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
    Figure 58. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Frequently Asked Questions
Benign Prostatic Hyperplasia (BPH) Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Benign Prostatic Hyperplasia (BPH) Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Benign Prostatic Hyperplasia (BPH) Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Glass Baby Bottle

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More

Copper Pen Nib

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More